Antimicrobial resistance (AMR) is an ongoing and growing global health crisis, causing increases in mortality, higher risks of routine medical procedures, and increased economic burden . AMR surveillance is key to understand the extent of resistance, developing and monitoring effective intervention strategies as well as identifying new and emerging resistance threats. In response to growing resistance, the World Health Organisation (WHO) launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015, with the aims of establishing the first global collaborative effort to standardise AMR surveillance . Participation in the programme has grown from 729 surveillance sites in 22 countries in 2017, to 24 803 surveillance sites in 70 countries reported in 2019 . Whilst this shows positive trends, the high rates of resistance observed stress the importance of ongoing and harmonised global AMR surveillance. Furthermore, concerns and predictions have highlighted that the COVID-19 outbreak could further exacerbate AMR , and decreases in surveillance capacity could reduce the ability to provide AMR data during the pandemic .